Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Multiple Myeloma
- Interventions
- Registration Number
- NCT04975997
- Lead Sponsor
- Celgene
- Brief Summary
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
- Detailed Description
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM). Approximately 200 patients randomized in stage 1 to one of three iberdomide dose levels of 1, 1.3, or 1.6 mg in combination with daratumumab and dexamethasone (Treatment Arms A1, A2, or A3), or to the DVd comparator arm (Treatment Arm B).
In Stage 2 of the study, approximately 664 additional subjects will be randomized 1:1 between 2 treatment arms:
* Approximately 332 subjects will be randomized to receive Treatment Arm A (IberDd)
* Approximately 332 subjects will be randomized to receive Treatment Arm B (DVd)
Participants in both treatment arms will continue to receive treatment until confirmed progressive disease (PD), unacceptable toxicity or withdrawal of consent. To ensure accuracy and completeness of the primary endpoint assessment of progression-free survival (PFS), participants who permanently discontinue study treatment for any reason, other than confirmed PD or withdrawal of consent, will continue to be followed for disease assessment.
The study will be conducted in compliance with International Council for Harmonisation (ICH) and Good Clinical Practices (GCPs).
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 864
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Daratumumab in combination with Iberdomide and dexamethasone - Dose 1 Dexamethasone Participants will receive oral iberdomide, subcutaneous daratumumab and oral dexamethasone. Daratumumab in combination with Iberdomide and dexamethasone - Dose 1 Daratumumab Participants will receive oral iberdomide, subcutaneous daratumumab and oral dexamethasone. Daratumumab in combination with Iberdomide and dexamethasone - Dose 1 Iberdomide Participants will receive oral iberdomide, subcutaneous daratumumab and oral dexamethasone. Daratumumab in combination with Iberdomide and dexamethasone - Dose 2 Daratumumab - Daratumumab in combination with Iberdomide and dexamethasone - Dose 2 Iberdomide - Daratumumab in combination with Iberdomide and dexamethasone - Dose 2 Dexamethasone - Daratumumab in combination with Iberdomide and dexamethasone - Dose 3 Dexamethasone - Daratumumab in combination with Iberdomide and dexamethasone - Dose 3 Daratumumab - Daratumumab in combination with Iberdomide and dexamethasone - Dose 3 Iberdomide - Daratumumab in combination with dexamethasone and bortezomib Dexamethasone Participants will receive subcutaneous daratumumab, bortezomib and oral dexamethasone Daratumumab in combination with dexamethasone and bortezomib Bortezomib Participants will receive subcutaneous daratumumab, bortezomib and oral dexamethasone Daratumumab in combination with dexamethasone and bortezomib Daratumumab Participants will receive subcutaneous daratumumab, bortezomib and oral dexamethasone
- Primary Outcome Measures
Name Time Method Progression-free Survival (PFS) Up to approximately 5 years To compare the efficacy of iberdomide (also known as BMS-986382), daratumumab, and dexamethasone (IberDd) to that of daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM) in terms of progression free survival (PFS).
Minimal Residual Disease (MRD) negative Complete Response (CR) at any time Up to approximately 5 years To compare the efficacy of iberdomide (also known as BMS-986382), daratumumab, and dexamethasone (IberDd) to that of daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM) in terms of minimal residual disease (MRD) negative complete response (CR) at any time.
- Secondary Outcome Measures
Name Time Method Time to Next Treatment (TTNT) Up to approximately 5 years Time from randomization to the start of the next antimyeloma treatment.
Overall Survival (OS) Up to approximately 5 years To evaluate clinical efficacy in terms of overall survival (OS) in participants with relapsed or refractory multiple myeloma (RRMM) treated with iberdomide, daratumumab, and dexamethasone (IberDd) compared to daratumumab, bortezomib, and dexamethasone (DVd).
Sustainability of Minimal Residual Disease (MRD) negativity Up to approximately 5 years To evaluate the sustainability of minimal residual disease (MRD) negativity.
Overall Response Rate (ORR) Up to approximately 5 years Calculated as percentage of participants who achieve best response of partial response (PR) or better according to the IMWG Uniform Response Criteria for multiple myeloma.
Time to response (TTR) Up to approximately 5 years Time from randomization to the first documentation of response (PR or better).
Duration of Response (DoR) Up to approximately 5 years Time from the first documentation of response (PR or better) to the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first.
Time to Progression (TTP) Up to approximately 5 years The time from randomization to the first documented disease progression.
Progression-free Survival 2 (PFS2) Up to approximately 5 years Time from randomization to progression on the next anti-myeloma treatment or death due to any cause, whichever occurs first.
Safety Up to approximately 5 years Type, frequency, seriousness and severity of adverse events (AEs), and relationship of AEs to study treatment.
European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Up to approximately 5 years Mean changes from baseline in subscale scores in subject-reported health related quality of life outcomes and multiple myeloma-related symptoms as measured by the EORTC QLQ-C30.
European Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20) Up to approximately 5 years EORTC QLQ-MY20 is a 20-item myeloma module intended for use among participants varying in disease stage and treatment modality. Mean changes from baseline in subscale scores in subject-reported health related quality of life outcomes and multiple myeloma-related symptoms as measured by the EORTC QLQ- MY20.
Recommended iberdomide dose for Stage 2 Up to approximately 1 year Area under the plasma concentration-time curve from time zero to tau (AUC(TAU)) Up to approximately 1 year Maximum plasma concentration (Cmax) Up to approximately 1 year Time to maximum plasma concentration (Tmax) Up to approximately 1 year
Trial Locations
- Locations (278)
Local Institution - 108
🇨🇦Quebec, Canada
Local Institution - 136
🇨🇳Guangzhou, China
Local Institution - 128
🇨🇳Hangzhou City, China
Local Institution - 120
🇨🇳Hangzhou, Zhejiang, China
Local Institution - 127
🇨🇳Harbin, China
Local Institution - 035
🇺🇸Hot Springs, Arkansas, United States
The Oncology Institute Of Hope And Innovation
🇺🇸Cerritos, California, United States
Local Institution - 683
🇺🇸Corona, California, United States
Los Angeles Cancer Network - Fountain Valley
🇺🇸Fountain Valley, California, United States
USC Norris Comprehensive Cancer Center
🇺🇸Newport, California, United States
Yale University School Of Medicine
🇺🇸New Haven, Connecticut, United States
Local Institution - 029
🇺🇸Fort Myers, Florida, United States
Local Institution - 049
🇺🇸Jacksonville, Florida, United States
Ocala Oncology Center
🇺🇸Ocala, Florida, United States
Local Institution - 028
🇺🇸Saint Petersburg, Florida, United States
BRCR Global
🇺🇸Tamarac, Florida, United States
Local Institution - 034
🇺🇸West Palm Beach, Florida, United States
Cleveland Clinic Florida
🇺🇸Weston, Florida, United States
Emory University School of Medicine
🇺🇸Atlanta, Georgia, United States
Alexian Brothers Hospital Network
🇺🇸Elk Grove Village, Illinois, United States
Local Institution - 689
🇺🇸Urbana, Illinois, United States
Northwest Cancer Center
🇺🇸Dyer, Indiana, United States
Norton Cancer Institute - St. Matthews Campus
🇺🇸Louisville, Kentucky, United States
Local Institution - 041
🇺🇸Alexandria, Louisiana, United States
Our Lady of the Lake Cancer Institute
🇺🇸Baton Rouge, Louisiana, United States
Local Institution - 027
🇺🇸Baton Rouge, Louisiana, United States
Local Institution - 696
🇺🇸New Orleans, Louisiana, United States
Greater Baltimore Medical Center
🇺🇸Baltimore, Maryland, United States
Center For Cancer And Blood Disorders
🇺🇸Bethesda, Maryland, United States
Maryland Oncology Hematology (Columbia) - USOR
🇺🇸Columbia, Maryland, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
University of Massachusetts Memorial Medical Center
🇺🇸Worcester, Massachusetts, United States
Minnesota Oncology Hematology, P.A. - Burnsville
🇺🇸Burnsville, Minnesota, United States
Local Institution - 694
🇺🇸Kansas City, Missouri, United States
HCA Midwest Health
🇺🇸Kansas City, Missouri, United States
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana
🇺🇸Billings, Montana, United States
Local Institution - 015
🇺🇸Summit, New Jersey, United States
Local Institution - 042
🇺🇸Bay Shore, New York, United States
Manhattan Hematology Oncology Center
🇺🇸New York, New York, United States
Duke University Hospital
🇺🇸Durham, North Carolina, United States
TriHealth, Good Samaritan Hospital
🇺🇸Cincinnati, Ohio, United States
Local Institution - 644
🇺🇸Cincinnati, Ohio, United States
Local Institution - 037
🇺🇸Cleveland, Ohio, United States
Cleveland Clinic - Taussig Cancer Institute
🇺🇸Cleveland, Ohio, United States
Ohio Health Corporation
🇺🇸Columbus, Ohio, United States
Oklahoma Cancer Specialists and Research Institute
🇺🇸Tulsa, Oklahoma, United States
Oregon Health and Science University
🇺🇸Portland, Oregon, United States
Local Institution - 048
🇺🇸Hershey, Pennsylvania, United States
Tennessee Oncology
🇺🇸Chattanooga, Tennessee, United States
Tennessee Oncology - Nashville
🇺🇸Nashville, Tennessee, United States
Texas Oncology-Austin Midtown
🇺🇸Austin, Texas, United States
Kelsey Seybold Clinic Berthelsen Main Campus
🇺🇸Houston, Texas, United States
Local Institution - 690
🇺🇸Houston, Texas, United States
USOR - Virginia Oncology Associates - Newport News
🇺🇸Newport News, Virginia, United States
Blue Ridge Cancer Care
🇺🇸Roanoke, Virginia, United States
Local Institution - 646
🇺🇸Vancouver, Washington, United States
University Of Wisconsin
🇺🇸Madison, Wisconsin, United States
Local Institution - 080
🇦🇷Ciudad Autanoma De Buenos Aires, Buenos Aires, Argentina
Local Institution - 083
🇦🇷Villa Elisa, Buenos Aires, Argentina
Local Institution - 813
🇦🇺Birtinya, Queensland, Australia
Local Institution - 812
🇦🇺Douglas, Queensland, Australia
Local Institution - 803
🇦🇺Adelaide, South Australia, Australia
Local Institution - 806
🇦🇺Bedford Park, South Australia, Australia
Local Institution - 802
🇦🇺Clayton, Victoria, Australia
Local Institution - 809
🇦🇺East Melbourne, Victoria, Australia
Local Institution - 801
🇦🇺Melbourne, Victoria, Australia
Local Institution - 811
🇦🇺Murdoch, Western Australia, Australia
Local Institution - 807
🇦🇺West Perth, Western Australia, Australia
Local Institution - 804
🇦🇺Camperdown, Australia
Local Institution - 800
🇦🇺Fitzroy, Australia
Local Institution - 808
🇦🇺Garran, Australia
Local Institution - 155
🇦🇹Graz, Austria
Local Institution - 154
🇦🇹Linz, Austria
Local Institution - 153
🇦🇹Salzburg, Austria
Local Institution - 156
🇦🇹St Polten, Austria
Local Institution - 150
🇦🇹Vienna, Austria
Local Institution - 151
🇦🇹Wien, Austria
Local Institution - 157
🇦🇹Wien, Austria
Local Institution - 172
🇧🇪Brugge, Belgium
Local Institution - 174
🇧🇪Bruxelles, Belgium
Local Institution - 056
🇧🇷Curitiba, Parana, Brazil
Local Institution - 058
🇧🇷Porto Alegre, RIO Grande DO SUL, Brazil
Local Institution - 050
🇧🇷Porto Alegre, RS, Brazil
Local Institution - 054
🇧🇷Jau, SAO Paulo, Brazil
Local Institution - 055
🇧🇷Sao Paulo, SP, Brazil
Local Institution - 051
🇧🇷Barretos, São Paulo, Brazil
Local Institution - 053
🇧🇷Rio de Janeiro, Brazil
Local Institution - 057
🇧🇷Sao Paulo, Brazil
Local Institution - 052
🇧🇷Sao Paulo, Brazil
Local Institution - 111
🇨🇦Calgary, Alberta, Canada
Local Institution - 103
🇨🇦Edmonton, Alberta, Canada
Local Institution - 112
🇨🇦Surrey, British Columbia, Canada
Local Institution - 104
🇨🇦Saint John, New Brunswick, Canada
Local Institution - 110
🇨🇦St John's, Newfoundland and Labrador, Canada
Local Institution - 101
🇨🇦Halifax, Nova Scotia, Canada
Local Institution - 109
🇨🇦Ottawa, Quebec, Canada
Local Institution - 107
🇨🇦Saskatoon, Saskatchewan, Canada
Local Institution - 141
🇨🇳Changsha, Hunan, China
Local Institution - 129
🇨🇳Nanchang, Jiangxi, China
Local Institution - 143
🇨🇳Xian, Shaanxi, China
Local Institution - 142
🇨🇳Shanghai, Shanghai, China
Local Institution - 145
🇨🇳Taiyuan, Shanxi, China
Local Institution - 144
🇨🇳Wenzhou, Zhejiang, China
Local Institution - 140
🇨🇳Beijing, China
Local Institution - 139
🇨🇳Beijing, China
Local Institution - 138
🇨🇳Beijing, China
Local Institution - 126
🇨🇳Changchun, China
Local Institution - 121
🇨🇳Chaoyang District, China
Local Institution - 135
🇨🇳Guangzhou, China
Local Institution - 134
🇨🇳Nanjing, China
Local Institution - 132
🇨🇳Shanghai, China
Local Institution - 130
🇨🇳Shanghai, China
Local Institution - 131
🇨🇳Shenyang, China
Local Institution - 124
🇨🇳Suzhu, China
Local Institution - 133
🇨🇳Tianjin, China
Local Institution - 137
🇨🇳Wuhan, China
Local Institution - 125
🇨🇳Xian, China
Local Institution - 123
🇨🇳Zhengzhou, China
Local Institution - 601
🇨🇿Brno, Czechia
Local Institution - 600
🇨🇿Ostrava-Poruba, Czechia
Local Institution - 602
🇨🇿Prague 2, Czechia
Local Institution - 371
🇩🇰Aalborg, Denmark
Local Institution - 370
🇩🇰Odense, Denmark
Local Institution - 372
🇩🇰Roskilde, Denmark
Local Institution - 231
🇫🇮Turku, Varsinais-Suomi, Finland
Local Institution - 230
🇫🇮Helsinki, Finland
Local Institution - 232
🇫🇮Oulu, Finland
Local Institution - 463
🇫🇷Argenteuil, France
Local Institution - 462
🇫🇷La Roche -Sur-Yon - Cedex 9, France
Local Institution - 451
🇫🇷Lille Cedex, France
Local Institution - 458
🇫🇷Nancy Cedex, France
Local Institution - 454
🇫🇷Nantes, France
Local Institution - 452
🇫🇷Paris Cedex, France
Local Institution - 456
🇫🇷Paris, France
Local Institution - 464
🇫🇷Pessac, France
Local Institution - 465
🇫🇷Rouen, France
Local Institution - 457
🇫🇷Toulouse Cedex 9, France
Local Institution - 308
🇩🇪Kiel, Schleswig-Holstein, Germany
Local Institution - 301
🇩🇪Frankfurt am Main, Germany
Local Institution - 300
🇩🇪Hamburg, Germany
Local Institution - 302
🇩🇪Hamburg, Germany
Local Institution - 305
🇩🇪Heidelberg, Germany
Local Institution - 304
🇩🇪Lubeck, Germany
Local Institution - 573
🇬🇷Patras, Achaea, Greece
Local Institution - 574
🇬🇷Patra, Achaia, Greece
Local Institution - 571
🇬🇷Athens, Greece
Local Institution - 572
🇬🇷Thessaloniki, Greece
Local Institution - 570
🇬🇷Thessaloniki, Greece
Local Institution - 932
🇮🇳Hyderabad, Andhra Pradesh, India
Local Institution - 930
🇮🇳Bangalore, Karnataka, India
Local Institution - 934
🇮🇳Ernakulam, Kerala, India
Local Institution - 933
🇮🇳Mumbai, Maharashtra, India
Local Institution - 935
🇮🇳Kolkata, West Bengal, India
Local Institution - 931
🇮🇳Pondicherry, India
Local Institution - 752
🇮🇪Cork, Ireland
Local Institution - 750
🇮🇪Dublin 9, Ireland
Local Institution - 751
🇮🇪Galway, Ireland
Local Institution - 918
🇯🇵Shinagawa-ku, Tokyo, Japan
Local Institution - 874
🇮🇱Afula, HaZafon, Israel
Local Institution - 872
🇮🇱Haifa, Israel
Local Institution - 871
🇮🇱Jerusalem, Israel
Local Institution - 870
🇮🇱Tel Aviv, Israel
Local Institution - 873
🇮🇱Tel Hashomer, Israel
Local Institution - 415
🇮🇹Roma, Lazio, Italy
Local Institution - 400
🇮🇹Bologna, Italy
Local Institution - 408
🇮🇹Catania, Italy
Local Institution - 414
🇮🇹Genova, Italy
Local Institution - 404
🇮🇹Milano, Italy
Local Institution - 407
🇮🇹Milano, Italy
Local Institution - 410
🇮🇹Novara, Italy
Local Institution - 412
🇮🇹Pavia, Italy
Local Institution - 402
🇮🇹Pisa, Italy
Local Institution - 405
🇮🇹Reggio Calabria, Italy
Local Institution - 413
🇮🇹Reggio Emilia, Italy
Local Institution - 401
🇮🇹Roma, Italy
Local Institution - 403
🇮🇹San Giovanni Rotondo FG, Italy
Local Institution - 409
🇮🇹Terni, Italy
Local Institution - 406
🇮🇹Udine, Italy
Local Institution - 905
🇯🇵Okayama, Japan
Local Institution - 900
🇯🇵Matsuyama, Ehime, Japan
Local Institution - 917
🇯🇵Higashi-Ibaraki-gun, Ibaraki, Japan
Local Institution - 919
🇯🇵Shimotsuga, Tochigi, Japan
Local Institution - 920
🇯🇵Nerima-ku, Tokyo, Japan
Local Institution - 915
🇯🇵Chuo-shi, Yamanashi, Japan
Local Institution - 912
🇯🇵Aomori, Japan
Local Institution - 916
🇯🇵Chiba, Japan
Local Institution - 908
🇯🇵Osaka-Sayama, Japan
Local Institution - 911
🇯🇵Fukuoka, Japan
Local Institution - 903
🇯🇵Kamogawa, Japan
Local Institution - 902
🇯🇵Kyoto-City, Japan
Local Institution - 910
🇯🇵Nagoya, Japan
Local Institution - 901
🇯🇵Nagoya, Japan
Local Institution - 907
🇯🇵Osaka, Japan
Local Institution - 913
🇯🇵Sapporo, Japan
Local Institution - 914
🇯🇵Sendai, Japan
Local Institution - 906
🇯🇵Shibuya-ku, Japan
Local Institution - 909
🇯🇵Shinagawa-ku, Tokyo, Japan
Local Institution - 904
🇯🇵Toyohashi, Japan
Local Institution - 974
🇰🇷Daegu, Korea, Republic of
Local Institution - 973
🇰🇷Gyeonggi-do, Korea, Republic of
Local Institution - 975
🇰🇷Hwasun-gun, Korea, Republic of
Local Institution - 971
🇰🇷Seoul, Korea, Republic of
Local Institution - 976
🇰🇷Seoul, Korea, Republic of
Local Institution - 972
🇰🇷Seoul, Korea, Republic of
Local Institution - 970
🇰🇷Seoul, Korea, Republic of
Local Institution - 977
🇰🇷Seoul, Korea, Republic of
Local Institution - 182
🇲🇽Mexico City, Distrito Federal, Mexico
Local Institution - 183
🇲🇽Guadalajara, Jalisco, Mexico
Local Institution - 181
🇲🇽La Raza, Mexico
Local Institution - 180
🇲🇽Mexico City, Mexico
Local Institution - 351
🇳🇱Dordrecht, Zuid-Holland, Netherlands
Local Institution - 354
🇳🇱Amsterdam, Netherlands
Local Institution - 352
🇳🇱Den Haag, Netherlands
Local Institution - 202
🇳🇴Bergen, Norway
Local Institution - 200
🇳🇴Oslo, Norway
Local Institution - 201
🇳🇴Trondheim, Norway
Local Institution - 631
🇵🇱Bialystok, Podlaskie, Poland
Local Institution - 633
🇵🇱Krakow, Poland
Local Institution - 635
🇵🇱Nowy Sacz, Poland
Local Institution - 634
🇵🇱Poznan, Poland
Local Institution - 636
🇵🇱Walbrzych, Poland
Local Institution - 630
🇵🇱Warszawa, Poland
Local Institution - 545
🇵🇹Coimbra, Portugal
Local Institution - 543
🇵🇹Lisboa, Portugal
Local Institution - 544
🇵🇹Lisboa, Portugal
Local Institution - 540
🇵🇹Porto, Portugal
Local Institution - 541
🇵🇹Porto, Portugal
Local Institution - 791
🇿🇦Pretoria, Gauteng, South Africa
Local Institution - 790
🇿🇦Cape Town, Western Cape, South Africa
Local Institution - 792
🇿🇦Kuils River, Western Cape, South Africa
Local Institution - 514
🇪🇸Pamplona, Navarra, Spain
Local Institution - 505
🇪🇸Barcelona, Spain
Local Institution - 502
🇪🇸Barcelona, Spain
Local Institution - 511
🇪🇸Barcelona, Spain
Local Institution - 501
🇪🇸Caceres, Spain
Local Institution - 509
🇪🇸Cordoba, Spain
Local Institution - 510
🇪🇸Madrid, Spain
Local Institution - 516
🇪🇸Madrid, Spain
Local Institution - 504
🇪🇸Madrid, Spain
Local Institution - 513
🇪🇸Madrid, Spain
Local Institution - 503
🇪🇸Malaga, Spain
Local Institution - 508
🇪🇸Murcia, Spain
Local Institution - 506
🇪🇸Oviedo, Spain
Local Institution - 515
🇪🇸Salamanca, Spain
Local Institution - 500
🇪🇸Santiago de Compostela, Spain
Local Institution - 512
🇪🇸Valencia, Spain
Local Institution - 507
🇪🇸Zaragoza, Spain
Local Institution - 272
🇸🇪Boras, Sweden
Local Institution - 271
🇸🇪Helsingborg, Sweden
Local Institution - 851
🇨🇭Chur, Switzerland
Local Institution - 850
🇨🇭St. Gallen, Switzerland
Local Institution - 955
🇨🇳Niao-Sung Hsiang Kaohsiung County, Taiwan
Local Institution - 952
🇨🇳Taichung City, Taiwan
Local Institution - 954
🇨🇳Taichung, Taiwan
Local Institution - 951
🇨🇳Tainan, Taiana, Taiwan
Local Institution - 956
🇨🇳Taipei, Zhongzheng Dist., Taiwan
Local Institution - 950
🇨🇳Taipei, Taiwan
Local Institution - 953
🇨🇳Taoyuan City, Taiwan
Local Institution - 778
🇹🇷Kavaklıdere, Ankara, Turkey
Local Institution - 776
🇹🇷Yenimahalle, Ankara, Turkey
Local Institution - 777
🇹🇷Pendik, Istanbul, Turkey
Local Institution - 771
🇹🇷Balçova, Izmir, Turkey
Local Institution - 775
🇹🇷Bornova, Izmir, Turkey
Local Institution - 773
🇹🇷Samsun, Kurupelit, Turkey
Local Institution - 770
🇹🇷Ankara, Turkey
Local Institution - 772
🇹🇷Gaziantep, Turkey
Local Institution - 774
🇹🇷Kayseri, Turkey
Local Institution - 702
🇬🇧Nottingham, Nottinghamshire, United Kingdom
Local Institution - 705
🇬🇧Belfast Northern Ireland, United Kingdom
Local Institution - 700
🇬🇧Birmingham, United Kingdom
Local Institution - 707
🇬🇧Canterbury Kent, United Kingdom
Local Institution - 704
🇬🇧Lancashire Blackpool, United Kingdom
Local Institution - 701
🇬🇧London, United Kingdom
Local Institution - 709
🇬🇧London, United Kingdom
Local Institution - 706
🇬🇧Oxford, United Kingdom
Local Institution - 711
🇬🇧Portsmouth, United Kingdom
Local Institution - 713
🇬🇧Sutton, United Kingdom
Local Institution - 708
🇬🇧Wolverhampton, United Kingdom